IPHA
Innate PharmaIPHA
IPHA
About: Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Employees: 177
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
11% more funds holding
Funds holding: 9 [Q4 2024] → 10 (+1) [Q1 2025]
11% more capital invested
Capital invested by funds: $255K [Q4 2024] → $282K (+$26.8K) [Q1 2025]
0.02% more ownership
Funds ownership: 0.17% [Q4 2024] → 0.19% (+0.02%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$11
479%
upside
Avg. target
$11
479%
upside
High target
$11
479%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth | 479%upside $11 | Buy Reiterated | 24 Apr 2025 |
Financial journalist opinion
Based on 5 articles about IPHA published over the past 30 days
Neutral
Business Wire
2 days ago
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, its proprietary ANKET® targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654), at the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. R-CHOP is an establish.
Neutral
Business Wire
2 weeks ago
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences.
Neutral
Business Wire
3 weeks ago
Outcome of Innate Pharma's 2025 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.
Neutral
Business Wire
3 weeks ago
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive forms of cutaneous T-cell lymphoma (CTCL). The results will be presented at the American Society of Clinical Oncol.
Neutral
Business Wire
3 weeks ago
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois. “We are looking forward to participating in the ASCO Annual Meeting 2025, where four abstracts with Innate's drugs in clinical developmen.
Neutral
Business Wire
1 month ago
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. Abstract details Antitumor characterization of IPH6501, a novel il2v-armed tetraspecifi.
Neutral
Seeking Alpha
1 month ago
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Corporate Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - Chief Executive Officer Yannis Morel - Chief Operating Officer Sonia Quaratino - Chief Medical Officer Frederic Lombard - Chief Financial Officer Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C.
Neutral
Business Wire
1 month ago
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2025. “The first quarter of 2025 was marked by significant progress across both our pipeline and strategic partnerships,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “Sanofi's €15 million equity investment reflects our shared conviction in the potential of ou.
Neutral
Business Wire
1 month ago
Innate Pharma announces conference call and webcast for Q1 2025 business update
MARSEILLE, France--(BUSINESS WIRE)-- #innatepharma--Innate Pharma announces conference call and webcast for Q1 2025 business update.
Neutral
Business Wire
1 month ago
Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2024 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 30, 2025. It can be downloaded (in French) on the Company's website and on the AMF's website. The Company also announced today the fil.
Charts implemented using Lightweight Charts™